Loading...
•
Nov 30, 2022
AngioDynamics Q2 2023 Earnings Report
AngioDynamics' Q2 2023 financial results were announced, revealing a sales increase and reaffirmed guidance.
Key Takeaways
AngioDynamics reported a 9.1% increase in net sales to $85.4 million for Q2 2023, with Med Tech sales up 29.7% and Med Device sales up 2.6%. The company's gross margin increased by 100 basis points to 52.8%. GAAP loss per share was $0.21, while adjusted earnings per share was $0.01.
Net sales increased by 9.1% to $85.4 million compared to the prior-year quarter.
Med Tech net sales increased by 29.7% to $24.5 million.
Med Device net sales increased by 2.6% to $60.9 million.
Gross margin increased by 100 basis points year over year to 52.8%.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Revenue by Segment
Med Tech Revenue
CapyFin.comMed Device Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Management is reaffirming its previously issued fiscal year 2023 guidance, expecting net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06.
Positive Outlook
- Net sales expected to be in the range of $342 to $348 million.
- Gross margin expected to be approximately 52.5% to 54.5%.
- Adjusted earnings per share expected to be in the range of $0.01 to $0.06.
- Continued investment in new product launches.
- Drive future growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income